These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 13783761)

  • 21. Gaps in our knowledge about transmission of vaccine-derived polioviruses.
    Fine PE
    Bull World Health Organ; 2000; 78(3):358-9. PubMed ID: 10812732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analysis of wild polioviruses towards the eradication of poliomyelitis from the Western Pacific Region.
    Hagiwara A; Yoneyama T; Yoshii K; Yoshida H; Shimizu H; Wada J; Thanh NT; Van Tu P; Miyamura T
    Jpn J Infect Dis; 1999 Aug; 52(4):146-9. PubMed ID: 10592893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
    Aylward RB; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Suggestion on the immunization period of Salk vaccine].
    BALESTRINI AM
    Dia Med; 1955 Jun; 27(42):1283. PubMed ID: 13241271
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effectiveness of different strategies of vaccine prophylaxis for poliomyelitis in the Ukraine].
    Moĭseieva HV; Zadorozhna VI
    Lik Sprava; 2002; (2):85-8. PubMed ID: 12073271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase contrast microprecipitin test with poliovirus antigens. II. Occurrence and development of microprecipitin antibody after natural inapparent infections, after inoculation of Salk vaccine, after feeding of attenuated live poliovirus vaccine, and in disease caused by polioviruses and other enteroviruses.
    EGGERS HJ; SABIN AB
    Arch Gesamte Virusforsch; 1961; 11():152-75. PubMed ID: 13725917
    [No Abstract]   [Full Text] [Related]  

  • 28. Continued Endemic Wild Poliovirus Transmission in Security-Compromised Areas - Nigeria, 2016.
    Nnadi C; Damisa E; Esapa L; Braka F; Waziri N; Siddique A; Jorba J; Nganda GW; Ohuabunwo C; Bolu O; Wiesen E; Adamu U
    MMWR Morb Mortal Wkly Rep; 2017 Feb; 66(7):190-193. PubMed ID: 28233765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress toward the global interruption of wild poliovirus type 2 transmission, 1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Aug; 48(33):736-8, 747. PubMed ID: 10503575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On the problem of vaccination reactions following oral immunization by poliomyelitis virus type I (Sabin)].
    LENNARTZ H
    Dtsch Med Wochenschr; 1963 Apr; 88():884-6. PubMed ID: 13929634
    [No Abstract]   [Full Text] [Related]  

  • 32. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?
    Ogra PL
    Public Health Rev; 1993-1994; 21(1-2):143-50. PubMed ID: 8041881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Poliomyelitis in The Netherlands, 1979-1991: immunity and exposure].
    Rümke HC; Oostvogel PM; van der Veer M; van Steenis G; van Loon AM
    Ned Tijdschr Geneeskd; 1993 Jul; 137(28):1380-6. PubMed ID: 8240513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.
    Etsano A; Damisa E; Shuaib F; Nganda GW; Enemaku O; Usman S; Adeniji A; Jorba J; Iber J; Ohuabunwo C; Nnadi C; Wiesen E
    MMWR Morb Mortal Wkly Rep; 2016 Aug; 65(30):770-3. PubMed ID: 27490081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Characterization of poliovirus vaccine strains isolated in the country with high level of immunization coverage].
    Samoĭlovich EO; Fel'dman EV; Beletskaia TS; Kapustnik LA; Svirchevskaia EIu; Ermolovich MA
    Vopr Virusol; 2002; 47(3):27-32. PubMed ID: 12173431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Observations on natural poliovirus infections in immunized children.
    GELFAND HM; FOX JP; LEBLANC DR
    Am J Public Health Nations Health; 1957 Apr; 47(4 Pt 1):421-31. PubMed ID: 13411317
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunity status to polioviruses among non-European union immigrants in Veneto Region (North-East Italy).
    Trivello R; Ngatchu T; Marin V; Moretti G; Malatesta R; Maini P; Moschen ME; Baldo V; De Marzi L; Majori S; Puppo A; Renzulli G
    Ann Clin Lab Sci; 1996; 26(2):154-9. PubMed ID: 8852425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management.
    Dowdle W; van der Avoort H; de Gourville E; Delpeyroux F; Desphande J; Hovi T; Martin J; Pallansch M; Kew O; Wolff C
    Risk Anal; 2006 Dec; 26(6):1449-69. PubMed ID: 17184392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.